A Phase 4 interventional study of carboxymethylcellulose 0.5%/glycerin 0.9% and sodium hyaluronate 0.18% in Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.
85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.
This study's enrollment of 80 is close to the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.
Browse Keratoconjunctivitis Sicca studies →Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Compared within Keratoconjunctivitis Sicca, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dry Eye Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Drug: carboxymethylcellulose 0.5%/glycerin 0.9%
1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Drug: sodium hyaluronate 0.18%
Drug page: Carboxymethylcellulose
1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Also known as: OPTIVE FUSION™
1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Also known as: VISMED® Multi
Change From Baseline in Global Ocular Staining Score in the Study Eye
Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.
Time frame: Baseline, Day 35
Change From Baseline in Global Ocular Staining Score in the Study Eye
Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.
Time frame: Baseline, Month 3
Change From Baseline in Ocular Surface Disease Index© (OSDI) Score
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.
Time frame: Baseline, Day 35
Change From Baseline in the Schirmer Test in the Study Eye
The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).
Time frame: Baseline, Day 35
Subject Assessment of Dry Eye Symptoms on a 5-Point Scale
Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).
Time frame: Baseline, Day 35, Month 3
Subject Global Assessment of Treatment Efficacy on a 5-Point Scale
Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).
Time frame: Baseline, Day 35, Month 3
Subject Assessment of Treatment Acceptability on a 5-Point Scale
Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).
Time frame: Day 35
Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale
Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).
Time frame: Day 35, Month 3
Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye
TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).
Time frame: Baseline, Day 35
Work Productivity and Activity Impairment Questionnaire Score
The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Baseline, Day 35, Month 3
Change From Baseline in Corneal Staining in the Study Eye
The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).
Time frame: Baseline, Day 35, Month 3
Change From Baseline in Conjunctival Staining in the Study Eye
The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).
Time frame: Baseline, Day 35, Month 3
Conjunctival Hyperaemia in the Study Eye
Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).
Time frame: Baseline, Day 35, Month 3
Study Product Use
The number of times the study product is administered per day is recorded.
Time frame: Day 8, Day 35, Month 3
| Milestone | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Started | 40 | 40 |
| Completed | 39 | 36 |
| Not completed | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Other reasons | 1 | 1 |
Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 5.2 ± 1.11 | 5.2 ± 1.21 |
| Change from Baseline at Day 35 | -1.5 ± 1.54 | -1.6 ± 1.54 |
Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 5.2 ± 1.11 | 5.2 ± 1.21 |
| Change from Baseline at Day 35 | -2.5 ± 2.23 | -2.4 ± 2.24 |
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 45.5 ± 22.02 | 44.4 ± 17.60 |
| Change from Baseline at Day 35 | -10.3 ± 13.51 | -12.9 ± 13.13 |
The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).
| Millimeters (mm)/5 Minutes | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 11.1 ± 10.22 | 8.7 ± 7.29 |
| Change from Baseline at Day 35 | 0.1 ± 7.74 | 1.0 ± 5.44 |
Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).
| Subjects | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline Stinging/Burning - None (N=32,28) | 0 | 1 |
| Baseline Stinging/Burning - Mild (N=32,28) | 7 | 4 |
| Baseline Stinging/Burning - Moderate (N=32,28) | 17 | 13 |
| Baseline Stinging/Burning - Severe (N=32,28) | 7 | 9 |
| Baseline Stinging/Burning - Very Severe (N=32,28) | 1 | 1 |
| Day 35 Stinging/Burning - None | 5 | 2 |
| Day 35 Stinging/Burning - Mild | 12 | 8 |
| Day 35 Stinging/Burning - Moderate | 17 | 17 |
| Day 35 Stinging/Burning - Severe | 1 | 3 |
| Day 35 Stinging/Burning - Very Severe | 0 | 1 |
| Month 3 Stinging/Burning - None | 5 | 6 |
| Month 3 Stinging/Burning - Mild | 14 | 5 |
| Month 3 Stinging/Burning - Moderate | 15 | 13 |
| Month 3 Stinging/Burning - Severe | 1 | 6 |
| Month 3 Stinging/Burning - Very Severe | 0 | 1 |
| Baseline Itching - None (N=32,28) | 6 | 5 |
| Baseline Itching - Mild (N=32,28) | 8 | 7 |
| Baseline Itching - Moderate (N=32,28) | 12 | 1 |
| Baseline Itching - Severe (N=32,28) | 6 | 3 |
| Baseline Itching - Very Severe (N=32,28) | 0 | 2 |
| Day 35 Itching- None | 10 | 8 |
| Day 35 Itching- Mild | 8 | 7 |
| Day 35 Itching- Moderate | 15 | 13 |
| Day 35 Itching- Severe | 2 | 2 |
| Day 35 Itching- Very Severe | 0 | 1 |
| Month 3 Itching- None | 10 | 10 |
| Month 3 Itching- Mild | 12 | 8 |
| Month 3 Itching- Moderate | 11 | 9 |
| Month 3 Itching- Severe | 2 | 3 |
| Month 3 Itching- Very Severe | 0 | 1 |
| Baseline Sandiness/Grittiness - None (N=32,28) | 2 | 1 |
| Baseline Sandiness/Grittiness - Mild (N=32,28) | 6 | 5 |
| Baseline Sandiness/Grittiness - Moderate (N=32,28) | 19 | 12 |
| Baseline Sandiness/Grittiness - Severe (N=32,28) | 5 | 8 |
| Bsln Sandiness/Grittiness-Very Severe (N=32,28) | 0 | 2 |
| Day 35 Sandiness/Grittiness - None | 7 | 4 |
| Day 35 Sandiness/Grittiness - Mild | 13 | 8 |
| Day 35 Sandiness/Grittiness - Moderate | 14 | 13 |
| Day 35 Sandiness/Grittiness - Severe | 1 | 4 |
| Day 35 Sandiness/Grittiness - Very Severe | 0 | 2 |
| Month 3 Sandiness/Grittiness - None | 7 | 8 |
| Month 3 Sandiness/Grittiness - Mild | 17 | 4 |
| Month 3 Sandiness/Grittiness - Moderate | 9 | 15 |
| Month 3 Sandiness/Grittiness - Severe | 2 | 3 |
| Month 3 Sandiness/Grittiness - Very Severe | 0 | 1 |
| Baseline Blurred Vision - None (N=32,28) | 11 | 10 |
| Baseline Blurred Vision - Mild (N=32,28) | 8 | 7 |
| Baseline Blurred Vision - Moderate (N=32,28) | 10 | 7 |
| Baseline Blurred Vision - Severe (N=32,28) | 3 | 3 |
| Baseline Blurred Vision - Very Severe (N=32,28) | 0 | 1 |
| Day 35 Blurred Vision - None | 16 | 13 |
| Day 35 Blurred Vision - Mild | 10 | 9 |
| Day 35 Blurred Vision - Moderate | 8 | 7 |
| Day 35 Blurred Vision - Severe | 1 | 1 |
| Day 35 Blurred Vision - Very Severe | 0 | 1 |
| Month 3 Blurred Vision - None | 20 | 14 |
| Month 3 Blurred Vision - Mild | 7 | 9 |
| Month 3 Blurred Vision - Moderate | 6 | 5 |
| Month 3 Blurred Vision - Severe | 1 | 1 |
| Month 3 Blurred Vision - Very Severe | 1 | 2 |
| Baseline Dryness - None (N=32,28) | 1 | 1 |
| Baseline Dryness - Mild (N=32,28) | 2 | 2 |
| Baseline Dryness - Moderate (N=32,28) | 13 | 10 |
| Baseline Dryness - Severe (N=32,28) | 13 | 12 |
| Baseline Dryness - Very Severe (N=32,28) | 3 | 3 |
| Day 35 Dryness - None | 4 | 3 |
| Day 35 Dryness - Mild | 8 | 5 |
| Day 35 Dryness - Moderate | 16 | 14 |
| Day 35 Dryness - Severe | 7 | 7 |
| Day 35 Dryness - Very Severe | 0 | 2 |
| Month 3 Dryness - None | 2 | 3 |
| Month 3 Dryness - Mild | 12 | 5 |
| Month 3 Dryness - Moderate | 17 | 14 |
| Month 3 Dryness - Severe | 4 | 6 |
| Month 3 Dryness - Very Severe | 0 | 3 |
| Baseline Light Sensitivity - None (N=32,28) | 1 | 2 |
| Baseline Light Sensitivity - Mild (N=32,28) | 4 | 8 |
| Baseline Light Sensitivity - Moderate (N=32,28) | 14 | 6 |
| Baseline Light Sensitivity - Severe (N=32,28) | 9 | 7 |
| Baseline Light Sensitivity - Very Severe (N=32,28) | 4 | 5 |
| Day 35 Light Sensitivity - None | 5 | 2 |
| Month 3 Light Sensitivity - Severe | 5 | 8 |
| Month 3 Light Sensitivity - Very Severe | 1 | 3 |
| Day 35 Light Sensitivity - Mild | 6 | 7 |
| Day 35 Light Sensitivity - Moderate | 18 | 11 |
| Day 35 Light Sensitivity - Severe | 5 | 7 |
| Day 35 Light Sensitivity - Very Severe | 1 | 4 |
| Month 3 Light Sensitivity - None | 5 | 2 |
| Month 3 Light Sensitivity - Mild | 16 | 10 |
| Month 3 Light Sensitivity - Moderate | 8 | 8 |
| Baseline Painful or Sore - None (N=31,28) | 0 | 1 |
| Baseline Painful or Sore - Mild (N=31,28) | 12 | 8 |
| Baseline Painful or Sore - Moderate (N=31,28) | 15 | 13 |
| Baseline Painful or Sore - Severe (N=31,28) | 4 | 4 |
| Baseline Painful or Sore - Very Severe (N=31,28) | 0 | 2 |
| Day 35 Painful or Sore - None | 5 | 5 |
| Day 35 Painful or Sore - Mild | 20 | 9 |
| Day 35 Painful or Sore - Moderate | 9 | 13 |
| Day 35 Painful or Sore - Severe | 1 | 2 |
| Day 35 Painful or Sore - Very Severe | 0 | 2 |
| Month 3 Painful or Sore - None | 5 | 9 |
| Month 3 Painful or Sore - Mild | 17 | 3 |
| Month 3 Painful or Sore - Moderate | 10 | 16 |
| Month 3 Painful or Sore - Severe | 2 | 2 |
| Month 3 Painful or Sore - Very Severe (N=34,31) | 0 | 1 |
| Baseline Other - None (N=3,1) | 0 | 0 |
| Baseline Other - Mild (N=3,1) | 0 | 0 |
| Baseline Other - Moderate (N=3,1) | 1 | 0 |
| Baseline Other - Severe (N=3,1) | 0 | 0 |
| Baseline Other - Very Severe (N=3,1) | 0 | 1 |
| Day 35 Other - None (N=1,3) | 0 | 0 |
| Day 35 Other - Mild (N=1,3) | 0 | 0 |
| Day 35 Other - Moderate (N=1,3) | 1 | 1 |
| Day 35 Other - Severe (N=1,3) | 0 | 1 |
| Day 35 Other - Very Severe (N=1,3) | 0 | 1 |
| Month 3 Other - None (N=1,3) | 0 | 1 |
| Month 3 Other - Mild (N=1,3) | 0 | 0 |
| Month 3 Other - Moderate (N=1,3) | 1 | 0 |
| Month 3 Other - Severe (N=1,3) | 0 | 1 |
| Month 3 Other - Very Severe (N=1,3) | 0 | 1 |
Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).
| Subjects | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Day 35 - Much Worse | 0 | 0 |
| Day 35 - Worse | 0 | 3 |
| Day 35 - About the Same | 12 | 11 |
| Day 35 - Improved | 21 | 14 |
| Day 35 - Much Improved | 2 | 3 |
| Month 3 - Much Worse | 0 | 1 |
| Month 3 - Worse | 0 | 3 |
| Month 3 - About the Same | 11 | 10 |
| Month 3 - Improved | 19 | 13 |
| Month 3 - Much Improved | 5 | 4 |
Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).
| Subjects | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Liked - Strongly Agree (N=35,30) | 14 | 8 |
| Liked - Agree (N=35,30) | 12 | 10 |
| Liked - Neither Agree nor Disagree (N=35,30) | 6 | 9 |
| Liked - Disagree (N=35,30) | 2 | 2 |
| Liked - Strongly Disagree (N=35,30) | 1 | 1 |
| Comfortable - Strongly Agree | 9 | 9 |
| Comfortable - Agree | 16 | 13 |
| Comfortable - Neither Agree nor Disagree | 7 | 6 |
| Comfortable - Disagree | 2 | 2 |
| Comfortable - Strongly Disagree | 1 | 1 |
Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).
| Subjects | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Day 35 - Very Satisfactory | 13 | 8 |
| Day 35 - Satisfactory | 17 | 19 |
| Day 35 - Poor | 5 | 4 |
| Day 35 - Very Poor | 0 | 0 |
| Month 3 - Very Satisfactory | 15 | 10 |
| Month 3 - Satisfactory | 15 | 11 |
| Month 3 - Poor | 5 | 9 |
| Month 3 - Very Poor | 0 | 1 |
TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).
| Seconds | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 5.52 ± 2.575 | 5.75 ± 3.146 |
| Change from Baseline at Day 35 | 0.6 ± 1.66 | 0.7 ± 2.00 |
The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline - Work Productivity (N=11,13) | 3.09 ± 1.921 | 3.46 ± 3.382 |
| Baseline - Activity Impairment | 3.91 ± 2.035 | 4.35 ± 2.550 |
| Day 35 - Work Productivity (N=11,9) | 2.55 ± 1.809 | 2.33 ± 1.936 |
| Day 35 - Activity Impairment (N=34,31) | 3.09 ± 2.065 | 3.52 ± 2.393 |
| Month 3 - Work Productivity (N=11,10) | 1.82 ± 0.982 | 2.40 ± 2.066 |
| Month 3 - Activity Impairment | 2.14 ± 1.630 | 2.77 ± 2.232 |
The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline | 1.7 ± 0.68 | 1.9 ± 0.65 |
| Change from Baseline at Day 35 | -0.4 ± 0.77 | -0.7 ± 0.83 |
| Change from Baseline at Month 3 | -0.8 ± 0.84 | -0.9 ± 1.04 |
The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).
| Scores on a Scale | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline - Temporal | 1.7 ± 0.64 | 1.6 ± 0.81 |
| Change from Baseline at Day 35 - Temporal | -0.5 ± 0.66 | -0.5 ± 0.81 |
| Change from Baseline at Month 3 - Temporal | -0.8 ± 0.79 | -0.8 ± 0.92 |
| Baseline - Nasal | 1.9 ± 0.66 | 1.7 ± 0.70 |
| Change from Baseline at Day 35 - Nasal | -0.6 ± 0.65 | -0.5 ± 0.68 |
| Change from Baseline at Month 3 - Nasal | -0.9 ± 0.97 | -0.7 ± 0.87 |
Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).
| Subjects | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Baseline - None | 8 | 8 |
| Baseline - Trace | 13 | 11 |
| Baseline - Mild | 13 | 10 |
| Baseline - Moderate | 1 | 2 |
| Baseline Severe | 0 | 0 |
| Day 35 - None | 17 | 12 |
| Day 35 - Trace | 9 | 10 |
| Day 35 - Mild | 9 | 8 |
| Day 35 - Moderate | 0 | 1 |
| Day 35 - Severe | 0 | 0 |
| Month 3 - None | 22 | 14 |
| Month 3 - Trace | 8 | 7 |
| Month 3 - Mild | 5 | 9 |
| Month 3 - Moderate | 0 | 1 |
| Month 3 - Severe | 0 | 0 |
The number of times the study product is administered per day is recorded.
| Number of Times/Day | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Day 8 | 3.63 ± 1.190 | 3.47 ± 0.900 |
| Day 35 | 3.77 ± 1.285 | 3.39 ± 0.761 |
| Month 3 | 3.71 ± 1.178 | 3.42 ± 0.958 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPTIVE FUSION™ | — | 0/40 (0%) | 4/40 (10%) |
| VISMED® Multi | — | 1/40 (2.5%) | 6/40 (15%) |
| Event | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| PericarditisCardiac disorders | 0/40 | 1/40 |
| Event | OPTIVE FUSION™ | VISMED® Multi |
|---|---|---|
| Dry EyeEye disorders | 0/40 | 2/40 |
| Eye DischargeEye disorders | 0/40 | 2/40 |
| Eye IrritationEye disorders | 2/40 | 2/40 |
| Eye PruritusEye disorders | 2/40 | 0/40 |
| Age, Customized(Participants) | OPTIVE FUSION™ | VISMED® Multi | Total |
|---|---|---|---|
| <65 years | 17 | 25 | 42 |
| ≥65 years | 23 | 15 | 38 |
| Sex: Female, Male(Participants) | OPTIVE FUSION™ | VISMED® Multi | Total |
|---|---|---|---|
| Female | 36 | 33 | 69 |
| Male | 4 | 7 | 11 |
Ran from May 2014 to primary completion in Jan 2015, 8 months.
Results were first posted in Feb 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboxymethylcellulose · Hyaluronic Acid